### SEC Form 4

 $\square$ 

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

|                    | ROVAL     |
|--------------------|-----------|
| OMB Number:        | 3235-0287 |
| Estimated average  | burden    |
| hours per response | : 0.5     |

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5           |
| obligations may continue. See          |
| Instruction 1(b).                      |

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person <sup>*</sup><br>Basil Michelle L |                     |          | 2. Issuer Name and Ticker or Trading Symbol<br>HAEMONETICS CORP [ HAE ] |   | ationship of Reporting Pe<br>k all applicable)<br>Director | 10% Owner                              |  |  |  |  |
|--|---------------------|----------|---|---|--|--|--|--|--|--|
| (Last)<br>125 SUMMEI   | (First)<br>R STREET | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year)<br>05/15/2023          | Х   | Officer (give title<br>below)<br>EVP and Genera            | Other (specify<br>below)<br>Il Counsel |  |  |  |  |
| (Street)<br>BOSTON   |                     |          | 4. If Amendment, Date of Original Filed (Month/Day/Year)                | 6. Individual or Joint/Group Filing (Check Applicable<br>Line)<br>X Form filed by One Reporting Person<br>Form filed by More than One Reporting<br>Person |  |  |  |  |  |  |
| (City)   | (State)             | (Zip)    | Rule 10b5-1(c) Transaction Indication                                   |   |  |  |  |  |  |  |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transaction<br>Code (Instr.<br>8) |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and<br>5) |               |         | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |
|---------------------------------|--|---|---|---|---|---------------|---------|---|---|---|
|                                 |  |   | Code                                    | v | Amount  | (A) or<br>(D) | Price   | Transaction(s)<br>(Instr. 3 and 4)  |   | (Instr. 4)  |
| Common Stock                    | 05/15/2023                                 |   | A                                       |   | 4,205 <sup>(1)</sup>  | A             | (2)     | 36,456 <sup>(3)</sup>   | D   |   |
| Common Stock                    | 05/16/2023                                 |   | F                                       |   | 446 <sup>(4)</sup>  | D             | \$89.21 | 36,010 <sup>(3)</sup>   | D   |   |

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| (e.g., puis, cans, warrants, options, convertible securities) |   |  |   |                                 |   |   |                                     |   |                    |                 |  |   |       |  |                                       |
|---|---|--|---|---------------------------------|---|---|-------------------------------------|---|--------------------|-----------------|--|---|-------|--|---------------------------------------|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)           | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transac<br>Code (li<br>8) |   | 5. Nun<br>of<br>Deriva<br>Securi<br>Acquii<br>(A) or<br>Dispos<br>of (D)<br>(Instr.<br>and 5) | tive<br>ities<br>red<br>sed<br>3, 4 | Expiration Date<br>(Month/Day/Year)<br>ed |                    | e Amount of     |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) |       | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4) |
|   |   |  |   | Code                            | v | (A)   | (D)                                 | Date<br>Exercisable                       | Expiration<br>Date | Title           | Amount<br>or<br>Number<br>of<br>Shares |   |       |  |                                       |
| Non-<br>qualified<br>Stock<br>Option<br>(Right to<br>Buy)     | \$89.16   | 05/15/2023                                 |   | A                               |   | 9,502   |                                     | (5)                                       | 05/15/2030         | Common<br>Stock | 9,502                                  | \$0   | 9,502 | D  |                                       |

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

3. This number includes unvested RSUs previously reported.

4. Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.

5. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

#### <u>/s/ Thomas V. Powers,</u> attorney-in-fact for Ms. Basil

05/17/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.